Therapeutic Targeting of Complement C5a Receptors in HuntingtonÍs Disease

亨廷顿病补体 C5a 受体的治疗靶向

• 批准号: nhmrc : 1004455
• 负责人: A/Pr John O'Sullivan
• 金额: $ 31.23万
• 依托单位: The University of Queensland
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2011
• 资助国家: 澳大利亚
• 起止时间: 2011-01-01 至 2013-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/therapeutic-targeting-complement-huntingtons-disease/109035
• 关键词: Therapeutic; Targeting; Complement; C5a; Receptors

HuntingtonÍs disease is a genetic neurodegenerative condition leading to progressive cognitive and motor deficits and eventual death. This research aims to explore the role of immune and inflammatory pathways in the progression of disease in patients suffering HuntingtonÍs disease, as well as in an animal model of this condition. By exploring these immune and inflammatory pathways, we aim to identify novel therapeutic targets to treat HuntingtonÍs disease.

亨廷顿氏病是一种遗传性神经退行性疾病，导致进行性认知和运动缺陷，最终死亡。这项研究旨在探索免疫和炎症途径在亨廷顿舞蹈症患者疾病进展中的作用，以及这种疾病的动物模型。通过探索这些免疫和炎症途径，我们的目标是确定新的治疗靶点来治疗亨廷顿舞蹈症。